Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 3676 AL 3690

Are Alzheimer's disease and other neurodegenerative disorders caused by impaired signalling of insulin and other hormones?

Hölscher C, De Felice FG, Greig NH, Ferreira ST.

Neuropharmacology. 2018 Jul 1;136(Pt B):159. doi: 10.1016/j.neuropharm.2018.05.021. Epub 2018 May 18.

The cholinergic system in the pathophysiology and treatment of Alzheimer's disease

Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, Khachaturian AS, Vergallo A, Cavedo E, Snyder PJ, Khachaturian ZS.

Brain. 2018 Jul 1;141(7):1917-1933. doi: 10.1093/brain/awy132.

Iron and Alzheimer's Disease: An Update on Emerging Mechanisms

Lane DJR, Ayton S, Bush AI.

J Alzheimers Dis. 2018;64(s1):S379-S395. doi: 10.3233/JAD-179944.

Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume

Caldwell JZK, Berg JL, Shan G, Cummings JL, Banks SJ; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2018;64(1):79-89. doi: 10.3233/JAD-180028.

Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?

Deming Y, Li Z, Benitez BA, Cruchaga C.

Expert Opin Ther Targets. 2018 Jul;22(7):587-598. doi: 10.1080/14728222.2018.1486823. Epub 2018 Jun 20.

Blood pressure-lowering interventions to prevent dementia: a systematic review and meta-analysis

van Middelaar T, van Vught LA, van Gool WA, Simons EMF, van den Born BH, Moll van Charante EP, Richard E.

J Hypertens. 2018 Sep;36(9):1780-1787. doi: 10.1097/HJH.0000000000001829.

Role of GPR40 in pathogenesis and treatment of Alzheimer's disease and type 2 diabetic dementia

Chen JJ, Gong YH, He L.

J Drug Target. 2019 Apr;27(4):347-354. doi: 10.1080/1061186X.2018.1491979. Epub 2018 Jul 24.

Autotaxin⁻Lysophosphatidic Acid Signaling in Alzheimer's Disease

Ramesh S, Govindarajulu M, Suppiramaniam V, Moore T, Dhanasekaran M.

Int J Mol Sci. 2018 Jun 21;19(7):1827. doi: 10.3390/ijms19071827.

Biomarkers for Alzheimer's disease: from pathogenesis to drug development

Hashimoto K.

Eur Arch Psychiatry Clin Neurosci. 2018 Aug;268(5):441-442. doi: 10.1007/s00406-018-0912-4.

Alzheimer's Disease Model System Using Drosophila

Tsuda L, Lim YM.

Adv Exp Med Biol. 2018;1076:25-40. doi: 10.1007/978-981-13-0529-0_3.

Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer's disease

Harrison JE.

Alzheimers Res Ther. 2018 Jun 29;10(1):61. doi: 10.1186/s13195-018-0386-7.

Editorial: Plasma Biomarker for Alzheimer's Disease: Are We Ready Now for Clinical Practice and Drug Trials?

Nakamura A.

J Prev Alzheimers Dis. 2018;5(3):158-159. doi: 10.14283/jpad.2018.24.

The TRPM2 channel nexus from oxidative damage to Alzheimer's pathologies: An emerging novel intervention target for age-related dementia

Jiang LH, Li X, Syed Mortadza SA, Lovatt M, Yang W.

Ageing Res Rev. 2018 Nov;47:67-79. doi: 10.1016/j.arr.2018.07.002. Epub 2018 Jul 17.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias